Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

A sickle cell patient shares his unique story about how he found the treatment that should provide a cure. Meg also speaks ...

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

Agios Pharmaceuticals (AGIO) stock falls as a late-stage trial for its lead drug mitapivat in sickle cell disease indicate a ...

Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...

India has launched BIRSA 101, the nation’s first indigenous CRISPR-based gene therapy for Sickle Cell Disease, marking a ...

Union Minister of State (Independent Charge) for Science & Technology; Earth Sciences; MoS PMO, Personnel, Public Grievances, ...

In a step towards eliminating sickle cell disease, which disproportionately affects India’s tribal population, the government ...

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study ​of patients aged 16 and older, but failed to show a statistically ‌significant ...

Launching the therapy, Dr. Jitendra Singh declared that India has officially begun its decisive march toward a Sickle ...